Search

Ipsen SA.

Closed

SectorFinance

121.3 2.1

Overview

Share price change

24h

Current

Min

118.5

Max

121.8

Key metrics

By Trading Economics

Income

220M

334M

Sales

-2.9M

1.8B

P/E

Sector Avg

21.173

27.91

Dividend yield

1.22

Profit margin

18.354

Employees

5,358

EBITDA

-73M

637M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+20.42% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.22%

4.01%

Market Stats

By TradingEconomics

Market Cap

111M

9.4B

Previous open

119.2

Previous close

121.3

News Sentiment

By Acuity

34%

66%

113 / 528 Ranking in Finance

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Ipsen SA. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Ipsen SA. Forecast

Price Target

By TipRanks

20.42% upside

12 Months Forecast

Average 136.2 EUR  20.42%

High 148 EUR

Low 120 EUR

Based on 5 Wall Street analysts offering 12 month price targets forIpsen SA. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

99.85 / 104Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

113 / 528 Ranking in Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat